Organización Médica de Investigación (OMI)

Uruguay 725 PB , Buenos Aires, CP: 1015

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Ana Malvar

Daniel Politis

Margarita Alfie

Karen Daniela Román

Open studies

Breast Cancer

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZenecaSee more

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) - TROPION-Breast05 - AstraZenecaSee more

Glomerulonephritis

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB - ACTION3 - Dimerix Bioscience Pty LtdSee more

Alzheimer disease

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) - ADEPT-4 - Karuna TherapeuticsSee more

Cardiovascular disease

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more

Renal disease